Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.64 |
| ▸ | GPR132 | Q9UNW8 | 3/20 | 0.61 |
| ▸ | GPR34 | Q9UPC5 | 4/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.58 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.57 |
| ▸ | CDC25B | P30305 | 1/20 | 0.57 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.57 |
| ▸ | ITGAV | P06756 | 1/20 | 0.57 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1123264 | 0.92 | GPR132 (0.68) | PTPN1GPR132GPR34ITGB3ITGA2B | |
| SCHEMBL1123054 | 0.91 | GAA (0.63) | PTPN1GPR132ITGB3ITGB1ITGAV | |
| SCHEMBL27658914 | 0.87 | GPR132 (0.77) | PTPN1GPR132GPR34ITGB3ITGA2B | |
| SCHEMBL1123232 | 0.87 | GPR132 (0.77) | PTPN1GPR132GPR34ITGB3ITGA2B | |
| SCHEMBL1123299 | 0.87 | GPR132 (0.77) | PTPN1GPR132GPR34ITGB3ITGA2B | |
| SCHEMBL1123033 | 0.87 | GPR132 (0.77) | PTPN1GPR132GPR34ITGB3ITGA2B | |
| SCHEMBL27659028 | 0.86 | GPR132 (0.67) | PTPN1GPR132GPR34ITGB3ITGA2B | |
| SCHEMBL1122857 | 0.86 | GPR132 (0.67) | PTPN1GPR132GPR34ITGB3ITGA2B | |
| SCHEMBL1122757 | 0.86 | GPR132 (0.78) | PTPN1GPR132GPR34ITGB3ITGA2B | |
| SCHEMBL5921803 | 0.85 | PTPN1 (0.76) | PTPN1GPR132ITGB3ITGA2BPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644321-B1 | NEW BENZAMIDES AS PPATY MODULATORS | S A L V A T LAB SA (ES) | 2011-02-09 | — | — | EP | disclosed |
| US-20060160894-A1 | Benzamides as ppar modulators | LABORATORIOS S.A.L.V.A.T.,S.A. (ES) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160894-A1 | Benzamides as ppar modulators | PPARD, PPARA, PPARG | PTPN1 2708/4885GPR132 122/4885GPR34 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.